EICHORCondition: Advanced Solid Tumor · Head and Neck Squamous Cell Carcinoma · Bladder Carcinoma · Sponsor: Fusion Pharmaceuticals Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Key Inclusion Criteria: * Signed ICF prior to initiation of any study-specific procedures * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, or metastatic solid tumours * Refractory to all standard treatments, or for whom standard treatment is not available, or tolerable, or is contraindicated, or the participant refuses standard therapy * Measurable disease per RECIST v. 1.1 * Available tumour tissue (archival or fresh biopsy) * Adequate bone marrow, heart, liver, and kidney function Key Exclusion Criteria: * Prior systemic radiopharmaceutical therapy within six months prior to the first dose of \[111In\]-FPI-1967 * Prior radiation therapy (RT) to bone marrow \> 20 Gy * RT within 30 days prior to the first dose of \[111In\]-FPI-1967 * Prior anti-cancer treatment (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents) within a certain amount of time prior to administration of the first dose of \[111In\]-FPI-1967 * Concurrent serious co-morbidities that could limit participants' full participation and compliance
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| City of Hope | Duarte, California, United States | — |
| University of California, San Francisco | San Francisco, California, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| GC Murdoch | Murdoch, Western Australia, Australia | — |
| St Vincent's Hospital | Melbourne, Australia | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05363605